Prospective Geometric Analysis of Ultra-Widefield OCTA Characteristics in Central Serous Chorioretinopathy Patients

NCT07347119 | Not Yet Recruiting

• 1 other identifier: 2025KYPJ135
• Study Type: observational
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

By leveraging parameters including fractal dimension and topological index, we constructed a quantitative evaluation framework for ultra-widefield optical coherence tomography angiography (UWF-OCTA) images in patients with central serous chorioretinopathy (CSC), thus overcoming the limitations of conventional qualitative analysis.

Conditions

Central Serous Chorioretinopathy (CSC)

Keywords

Central Serous Chorioretinopathy; Ultra-Widefield Optical Coherence Tomography Angiography; Geometry

Outcome Measures

Primary Outcomes (1)

• Choroidal Vascular Fractal Dimension

  Choroidal vascular fractal dimension quantified from optical coherence tomography angiography (OCTA) images.

  Baseline, 1 month, 3 months, 6 months, and 12 months

Secondary Outcomes (7)

• Maximum subretinal fluid height

  Baseline, 1 month, 3 months, 6 months, and 12 months

• Subretinal fluid area

  Baseline, 1 month, 3 months, 6 months, and 12 months

• Subretinal fluid volume

  Baseline, 1 month, 3 months, 6 months, and 12 months

• Choroidal vascular branching index

  Baseline, 1 month, 3 months, 6 months, and 12 months

• Choroidal Vascular Connectivity Index

  Baseline, 1 month, 3 months, 6 months, and 12 months

Study Arms (4)

Acute Central Serous Chorioretinopathy

Clinically, serous retinal detachment (SRD) can be detected via fundus examination and optical coherence tomography (OCT), along with focal or multifocal retinal pigment epithelium (RPE) changes confined to small pigment epithelial detachment (PED) lesions. Fundus fluorescein angiography (FFA) demonstrates RPE leakage. SRD typically resolves within 3-4 months, and in most cases, no long-term symptoms persist except for color discrimination deficits in some patients.

Chronic Central Serous Chorioretinopathy

When the disease course exceeds 4-6 months, obvious multifocal atrophic retinal pigment epithelium (RPE) changes, multifocal leakage, and extensive RPE atrophy can be observed. Fundus autofluorescence (FAF) shows hypofluorescence in the RPE-damaged areas.

Recurrent Central Serous Chorioretinopathy

The patient has a history of one or more previous episodes, during which the symptoms completely resolved or significantly improved, and optical coherence tomography (OCT) examination showed complete absorption of subretinal fluid, with reattachment of the neurosensory retina. After complete remission of the first (or previous) episode (an interval of at least 3-6 months is generally considered), the patient develops typical symptoms of central serous chorioretinopathy (CSC) again, accompanied by objective evidence of the acute or chronic phase, such as changes detected by OCT or fundus fluorescein angiography (FFA).

Control Group

Healthy control subjects without any local or systemic diseases

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

The study subjects were recruited from outpatients of the Medical Retina Department at Zhongshan Ophthalmic Center, and eligible cases meeting the study criteria were selected from the outpatient medical record system.

You may qualify if:

• Adults aged 18 to 60 years, inclusive;
• Clinical diagnosis of central serous chorioretinopathy (CSC);
• Completion of fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA) examinations;
• Completion of ultra-widefield optical coherence tomography angiography (UWF-OCTA) imaging;
• No prior history of pharmacological or surgical treatment for CSC;
• Ability and willingness to provide written informed consent.

You may not qualify if:

• Presence of other ophthalmic diseases that may affect retinal or choroidal imaging or analysis, including but not limited to: Significant refractive media opacities interfering with OCTA imaging (e.g., severe cataract, vitreous hemorrhage);
• Presence of systemic diseases that may affect study outcomes or participant safety;
• Pregnant or lactating women;
• History of psychiatric or mental disorders that may impair compliance;
• Hemorrhagic diathesis or requirement for long-term anticoagulant therapy;
• History of long-term systemic medication use that may affect choroidal or retinal circulation;
• Presence of severe and/or uncontrolled comorbid medical conditions, including but not limited to:
• Uncontrolled diabetes mellitus; Uncontrolled hypertension; Active uncontrolled infection; Chronic obstructive pulmonary disease (COPD) with dyspnea at rest;
• History of intraocular surgery or intravitreal injection within the past 6 months;
• High refractive error defined as:
• Spherical equivalent (SE) \< -6.0 diopters or \> +3.0 diopters, or Axial length (AL) \> 26.0 mm;
• Any other condition that, in the opinion of the investigator, would make participation unsafe or interfere with protocol adherence.

Sponsors & Collaborators

• Sun Yat-sen University: lead

Study Sites (1)

Zhongshan Ophthalmic Center, Sun Yat-sen University

Guangzhou, Guangdong, 510060, China

Location

MeSH Terms

Conditions

Central Serous Chorioretinopathy

Condition Hierarchy (Ancestors)

Retinal Diseases; Eye Diseases

Study Officials

• Chenjin Jin, PH.D

  Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong 510060

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Rongtian Chen

CONTACT

16619724130; 376126340@qq.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of ophthalmology, Principal Investigator, Clinical Professor

Study Record Dates

• First Submitted: December 17, 2025
• First Posted: January 16, 2026
• Study Start: December 18, 2025
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): June 30, 2027
• Last Updated: January 16, 2026

Record last verified: 2026-01

Locations

CN (1)